Earnings Call Transcript

AI summary - Q1 FY27 revenue grew 6.3% y-y to INR187 Cr; EBITDA INR28.6 Cr, margin 15.3% - FY27 revenue growth guidance at least 30%, FY28 growth targeted over 60% - EBITDA margin expected 16-19% in Q2 FY27; FY28 margin to improve to ~25% post HFC-32 project - HFC-32 project commissioning on track for Q3 FY27; 65% capacity under long-term contracts - Solar grade DHF plant fully commissioned and ramped; 85% capacity contracted - Capex plans: INR30-40 Cr solar grade DHF expansion, INR120 Cr AHF expansion, INR150 Cr electronic grade - R&D focus on electronic grade chemicals with technology tie-ups; approval cycle ~1-1.5 years - Net debt-free post INR250 Cr QIP; strong balance sheet supports growth - Multiple analyst queries on margin outlook and project ramp-up; management confident on stable margins and ramp-up - Long-term strategy: move up fluorochemical value chain, expand fluoropolymers, HFOs, and specialty products